Skip to content
Open access

VGLL4 enhances PDK4 transcription and promotes metabolic dysfunction-associated fatty liver disease

Sep 2026 · EMBO Reports · Vol 27, pp. 5807 - 5836 · 0 citations · 46 references
Medicine

TL;DR

The VGLL4–TEAD4/CEBPA–PDK4 axis as a key driver of MAFLD is unveiled and its pharmacological blockade alleviates hepatic steatosis in model mice and represents a viable strategy to halt MAFLD progression.

Abstract

MAFLD is a global epidemic with a limited number of approved targeted therapies, underscoring the urgent need to define its underlying regulatory mechanisms. Here, we identify VGLL4 as a positive regulator of MAFLD progression. Hepatocyte-specific overexpression of Vgll4 induces hepatic steatosis, insulin resistance, and inflammation, whereas its knockout protects mice from HFD-induced metabolic dysfunction. Mechanistically, VGLL4 strengthens the interaction between TEAD4 and CEBPA and promotes the cooperative activation of Pdk4 expression. Functional studies identify PDK4 as a downstream effector, as its knockdown alleviates VGLL4-exacerbated hepatosteatosis in vivo. YAP attenuates this regulatory mechanism and suppresses Pdk4 transcription during hepatic steatosis. Notably, administration of Super-TDU, a peptide that disrupts the VGLL4–TEADs interaction, significantly alleviates hepatic steatosis in both HFD-fed mice and Vgll4-overexpressing mice. Our findings unveil the VGLL4–TEAD4/CEBPA–PDK4 axis as a key driver of MAFLD and demonstrate that its pharmacological blockade alleviates hepatic steatosis in model mice. Hepatic VGLL4 promotes MAFLD by enhancing steatosis and impairing insulin signaling. Mechanistically, VGLL4 promotes TEAD4/CEBPA-dependent PDK4 transcription, while disrupting VGLL4/TEAD4 binding alleviates fatty liver phenotypes. VGLL4 acts as a hepatocyte-specific driver of MAFLD progression. VGLL4 enhances TEAD4-CEBPA cooperation to activate Pdk4 transcription and promote hepatic lipid accumulation. Targeting the VGLL4/TEADs complex with Super-TDU represents a viable strategy to halt MAFLD progression. VGLL4 acts as a hepatocyte-specific driver of MAFLD progression. VGLL4 enhances TEAD4-CEBPA cooperation to activate Pdk4 transcription and promote hepatic lipid accumulation. Targeting the VGLL4/TEADs complex with Super-TDU represents a viable strategy to halt MAFLD progression. Hepatic VGLL4 promotes MAFLD by enhancing steatosis and impairing insulin signaling. Mechanistically, VGLL4 promotes TEAD4/CEBPA-dependent PDK4 transcription, while disrupting VGLL4/TEAD4 binding alleviates fatty liver phenotypes.

Read PDF

Similar papers

Sep 2026

PDCD4-driven steatosis via the HNF4A/GK axis is attenuated by the natural compound isosinensetin.

BACKGROUND Programmed cell death factor 4 (PDCD4) has been implicated in various metabolic disorders. However, its role and underlying mechanisms in metabolic dysfunction-associated steatotic liver disease (MASLD) have not been fully elucidated. PURPOSE This study aimed to define the role of PDCD4 in hepatic steatosi...

Xiao-Na Cheng, Kai-Kai Lu, Lu-Yun Yang et al. · 0 citations
Open access Sep 2026

NPAS2 promotes MASLD and hepatocarcinogenesis through SIRT1-mediated PPARγ suppression

Emerging evidence links circadian disruption to metabolic dysfunction-associated steatotic liver disease (MASLD), but the underlying mechanisms remain elusive. NPAS2, a core circadian regulator, has an undefined role in the pathogenesis of MASLD and its progression to hepatocellular carcinoma (HCC). This study aime...

Jiao Mu, Jia-Li Ye, Jia-Hao Zhang et al. · 0 citations
Oct 2026

WTAP/YTHDC1-mediated m6A modification of P4HA1 suppresses hepatic gluconeogenesis and ameliorates MASLD by activating AKT signaling.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global metabolic epidemic with limited therapeutic options. Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) has been implicated in glucose metabolism, but its functional role and regulatory mechanisms in MASLD remain unknown. In this study, we establish...

Xia Cai, Xiao-Jin Xu, Mo-Ran Zhang et al. · 0 citations
Open access Sep 2026

Arhgap25 Promotes Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by Driving Kupffer Cell Polarization via Activation of the AKT/mTOR Signaling Pathway.

BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading global health burden, yet the regulatory nodes linking hepatic immune dysregulation to metabolic perturbations remain incompletely understood. METHODS We integrated bulk and single-cell RNA sequencing (scRNA-seq) to identify core...

Yan Wang, Shuang-Shuang Lu · 0 citations
Sep 2026

Sinusoidal endothelial cells orchestrate liver inflammation and lipid metabolism via USP12/CD36 axis being the target of celastrol therapy.

Disordered lipid metabolism and inflammation, the hallmark features of metabolic dysfunction-associated steatohepatitis (MASH), present a significant therapeutic challenge even in the absence of obesity, making the discovery of novel pathogenic mechanisms and therapies imperative. Although Celastrol (Cel) markedly amel...

Hu Hua, Wen-Ping Zhu, Le-Hang Sun et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.